toxylact: a07bc03 crospovidone
The first professional lActological database in the word
Crospovidone (ATC A07BC03) is a non‑absorbed, cross‑linked polyvinylpyrrolidone polymer classified as an “other intestinal adsorbent”, used primarily as a pharmaceutic aid and enterosorbent, with negligible systemic absorption and a very low expected risk during breastfeeding.ebi+3
ATC A07BC03 overview
ATC code A07BC03 designates crospovidone within the subgroup A07BC “Other intestinal adsorbents”, part of the intestinal adsorbents class A07B among antidiarrheals. In addition to its classification as an antidiarrheal/adsorbent, crospovidone is widely used as a pharmaceutical excipient (tablet disintegrant and suspending agent) in many oral medicines.atcddd.fhi+5
Pharmacology and mechanism
Crospovidone is a synthetic, water‑insoluble, cross‑linked polyvinylpyrrolidone with high swelling capacity and rapid water uptake, which allows it to adsorb water and certain solutes in the gastrointestinal lumen. As an intestinal adsorbent, it can bind and immobilize various molecules in the gut contents, while its swelling and disintegrant properties help modify stool consistency and transit without systemic pharmacological activity.eureka.patsnap+3
Therapeutic and technological uses
Within A07BC03, crospovidone is categorized as an intestinal adsorbent for antidiarrheal use, though in practice its primary role is as a pharmaceutic aid (adsorbent, excipient) in oral formulations rather than as a stand‑alone antidiarrheal drug. As an excipient, it is incorporated into numerous tablets and capsules to ensure rapid disintegration and uniform dispersion, indirectly affecting the delivery of many active substances.ebi+4
Pharmacokinetics relevant to lactation
Crospovidone is a large, cross‑linked polymer that is not digested or absorbed from the gastrointestinal tract; it passes through the gut unchanged and is excreted in the feces. Because it does not enter the systemic circulation to a clinically relevant extent, it is not expected to be present in human milk in measurable amounts.drugs.ncats+2
Maternal safety profile
At the doses used in medicinal products and as an excipient, crospovidone is generally well tolerated and considered pharmacologically inert, with no specific systemic adverse effect profile when taken orally. Rare hypersensitivity reactions have been reported for polyvinylpyrrolidone derivatives in other contexts, but such events are exceptional and not characteristic of routine oral exposure.eureka.patsnap+2
Lactation safety assessment
General lactation principles and guideline documents emphasize that non‑absorbed oral agents and excipients are among the lowest‑risk categories, as they do not reach maternal plasma or breast milk in significant amounts. Given its non‑absorption, crospovidone is therefore considered to pose a negligible direct risk to breastfed infants, whether used as a classified intestinal adsorbent or as an excipient in maternal medications.who+5
Potential effects on the breastfed infant
Direct exposure of the infant to crospovidone via breast milk is expected to be essentially zero, so crospovidone‑related toxicity or interference with infant nutrition is not anticipated. Any potential risk for the infant in practice will derive from the active drugs formulated with crospovidone rather than from the polymer itself, so lactation risk assessment should focus on those active ingredients.who+5
Practical considerations in breastfeeding
When a breastfeeding woman receives an oral medication containing crospovidone—as an intestinal adsorbent or excipient—breastfeeding can generally continue without dose‑timing adjustments or special precautions related to crospovidone. As with other maternal medications, routine good practice is to use the lowest effective dose for the shortest duration and to monitor the infant for unexpected symptoms attributable to the active drug, not to the crospovidone component.who+2
Role among intestinal adsorbents
Compared with other A07BC adsorbents (pectin, kaolin, attapulgite, diosmectite), crospovidone has limited direct antidiarrheal evidence but a very well‑established record as an inert excipient and enterosorbent with negligible absorption. Its toxico‑lactological profile is therefore highly favorable, and it is unlikely to be a limiting factor in breastfeeding decisions when present in antidiarrheal products or other oral medicines.atcddd.fhi+5



